PSTV 8-K: Smart Summary

The 2026 Annual Meeting of Stockholders of Plus Therapeutics, Inc. was held on May 14, 2026, at which stockholders voted on four proposals: election of directors, ratification of auditors, advisory vote on executive compensation, and approval of the sixth amendment and restatement of the 2020 Stock Incentive Plan.

• Howard Clowes — 11,863,579 for / 2,186,724 against (84.45%)
• An van Es-Johansson, M.D. — 12,384,866 for / 1,665,437 against (88.16%)
• Richard J. Hawkins — 12,344,152 for / 1,706,151 against (87.87%)
• Marc H. Hedrick, M.D. — 12,350,511 for / 1,699,792 against (87.92%)
• Ronald A. Andrews — 12,417,138 for / 1,633,165 against (88.37%)
• Kyle Guse, Esq., MBA, CPA — 12,384,591 for / 1,665,712 against (88.15%)

• Ratification of Appointment of CBIZ CPAs, P.C. as Independent Registered Public Accounting Firm — 60,860,051 for / 2,292,062 against / 1,705,208 abstain (93.85%) — passed
• Advisory Vote on the Compensation of Named Executive Officers — 10,389,498 for / 3,364,694 against / 296,111 abstain (74.80%) — passed
• Sixth Amendment and Restatement of the Company's 2020 Stock Incentive Plan — 7,976,002 for / 5,648,887 against / 425,414 abstain (58.16%) — passed